Exploring how mechanical stress affects heart disease linked to specific genetic mutations.
Official title: Biomaterial Platforms to Model the Role of Mechanical Overload in MYBPC3-Linked Hypertrophic Cardiomyopathy
Funded at Washington University · NIH-10914885 · Data updated 2026-11-12
This study is looking at how extra strain on the heart affects people with a common inherited heart condition called Hypertrophic Cardiomyopathy (HCM), especially those with specific genetic changes, to help find better treatments that fit each person's needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $385,875 |
| NIH project number | 5R01HL159094-04 |
| Project ID | NIH-10914885 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Hypertrophic Cardiomyopathy, particularly those with MYBPC3 mutations.
✕Less likely to help
Patients without genetic mutations linked to Hypertrophic Cardiomyopathy or those with non-hereditary forms of heart disease may not benefit from this research.
What this research studies
This research investigates Hypertrophic Cardiomyopathy (HCM), a common inherited heart condition, by examining how mechanical overload on the heart interacts with genetic mutations. Using advanced techniques, including a micro-heart muscle model derived from human stem cells, the study aims to understand the molecular mechanisms that lead to heart remodeling in patients with MYBPC3 mutations. By simulating different levels of mechanical stress, researchers hope to identify why some patients develop HCM and how existing treatments may fail. This approach could lead to more effective therapies tailored to individual patient needs.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with Hypertrophic Cardiomyopathy, potentially reducing the risk of severe complications.
How similar studies have gone: Previous research has shown promise in understanding the role of mechanical factors in heart disease, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Huebsch, Nathaniel — Washington University
- Study coordinator: Huebsch, Nathaniel
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.